Lista de obras -

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

artículo científico publicado en 2005

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

artículo científico publicado en 2008

Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells

artículo científico publicado en 2008

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models

artículo científico publicado en 2009

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

artículo científico publicado en 2007

Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia

artículo científico publicado en 2004

Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.

artículo científico publicado en 2005

Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.

artículo científico publicado en 2008

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

artículo científico publicado en 2005

Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment

artículo científico publicado en 2009

In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma

artículo científico publicado en 2007

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells

artículo científico publicado en 2012

Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma

artículo científico publicado en 2008

Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells

artículo científico publicado en 2004

Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells

artículo científico publicado en 2006

Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice

artículo científico publicado en 2006

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer

artículo científico publicado en 2007

Lista de obras de

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models

Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer

Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia

Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells.

Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment

In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells

Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma

Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells

Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells

Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer